ALFA FinderBSE filing, NSE: MANKIND. Summary written from the filing by ALFA Finder's alert engine.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,640.00
- Market cap
- ₹1,09,044 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 48.6×Sector 43.7×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Other Announcement
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Other other announcement announcements
All →Religare Enterprises Other Announcement
Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.
Optivalue Tek Consulting Other Announcement
Optivalue Tek filed Acuité's half-yearly monitoring report on IPO proceeds for H1 FY2026-27. No deviation from the offer objects was observed.
5Paisa Capital Other Announcement
5paisa Capital Ltd filed its quarterly shareholding pattern under Regulation 31(1)(c). It reports routine holding figures with no new transaction or corporate event.
Chennai Meenakshi Multispeciality Hospital Other Announcement
Chennai Meenakshi Multispeciality Hospital issued a duplicate share certificate for 100 shares to Inder Chand Kothari L under folio 00008717. The intimation is routine share-certificate paperwork with no transaction or money involved.
Axel Polymers Other Announcement
Axel Polymers reports no deviation in utilisation of its Rs 11.18 Crore preferential issue proceeds for the quarter ended 30 September 2026. This is a routine Regulation 32 statement of deviation with a clean auditor certificate.
360 One Wam Other Announcement
360 ONE WAM disclosed PIT sales by five insiders on 12 November 2026, totalling about Rs 3.55 Crore. The sellers are designated persons, KMP and an employee's relative, with no promoter involved.
- Value
- ₹3.55 Cr